<div id="readability-page-1"><p>Swiss National Bank boosted its holdings in  IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 533,780 shares of the medical research company's stock after purchasing an additional 21,900 shares during the quarter. Swiss National Bank owned about 0.31% of IQVIA worth $84,118,000 at the end of the most recent quarter.</p><p>Several other institutional investors have also recently bought and sold shares of IQV. Artisan Partners Limited Partnership acquired a new position in shares of  IQVIA during the second quarter valued at about $515,772,000.  JPMorgan Chase &amp; Co. boosted its stake in  IQVIA by 45.7% during the 1st quarter. JPMorgan Chase &amp; Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after purchasing an additional 798,534 shares during the last quarter.  Nordea Investment Management AB increased its holdings in  IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company's stock worth $326,274,000 after purchasing an additional 606,391 shares in the last quarter.  Hawk Ridge Capital Management LP purchased a new stake in shares of  IQVIA in the first quarter worth approximately $77,096,000.  Finally, Nuveen LLC bought a new position in shares of  IQVIA in the first quarter valued at approximately $76,328,000. Institutional investors and hedge funds own  89.62% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities research analysts recently commented on the company. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of IQVIA in a research report on Wednesday, October 8th. TD Cowen downgraded shares of IQVIA from a &#34;buy&#34; rating to a &#34;hold&#34; rating and increased their target price for the company from $206.00 to $215.00 in a report on Monday, November 3rd. Robert W. Baird  set a $258.00 price target on shares of IQVIA and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, October 29th. Hsbc Global Res upgraded shares of IQVIA from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, October 9th. Finally, BMO Capital Markets began coverage on IQVIA in a research note on Thursday, November 13th. They issued an &#34;outperform&#34; rating and a $260.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued  a Buy rating and six have issued  a Hold rating to the stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and an average target price of $240.61.</p><p><b>View Our Latest Analysis on IQV</b></p><h2>Insider Transactions at IQVIA</h2><p>In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company's stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company's stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Corporate insiders own  1.60% of the company's stock. </p><h2>IQVIA Trading Up 3.7%</h2><p>Shares of IQV stock opened at $225.09 on Friday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market cap of $38.33 billion, a P/E ratio of 30.88, a PEG ratio of 2.52 and a beta of 1.34. The company has a 50 day moving average of $205.80 and a 200-day moving average of $181.06. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $228.12. </p><p>IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA's revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 earnings per share.  IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Sell-side analysts anticipate that  IQVIA Holdings Inc. will post 10.84 earnings per share for the current year. </p><h2>IQVIA Company Profile</h2> (Free Report)<p>IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology &amp; Analytics Solutions, Research &amp; Development Solutions, and Contract Sales &amp; Medical Solutions.</p><h2>Read More</h2><ul><li>Five stocks we like better than IQVIA</li><li>Compound Interest and Why It Matters When Investing</li><li>Red Cups or Red Flags: Starbucks’ Bet on a Holiday Recovery</li><li>Quiet Period Expirations Explained</li><li>MP Materials Stock Soared After Earnings—Here’s the Real Reason</li><li>How to Buy Cheap Stocks Step by Step</li><li>Why Palantir Slide May Be a Setup for a Long-Term Opportunity</li></ul><p><strong>Want to see what other hedge funds are holding IQV?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlRVg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in IQVIA Right Now?</h2><p>Before you consider IQVIA, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.</p><p>While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Swiss National Bank increased its stake in IQVIA Holdings Inc. by 4.3% in Q2, now holding 533,780 shares worth $84.12 million. Other institutional investors also boosted their holdings. Analysts have mixed ratings on IQVIA, with a consensus of 'Moderate Buy' and an average target price of $240.61. IQVIA's Q3 earnings beat estimates with $3.00 EPS and $4.10 billion revenue. The company has set its FY 2025 guidance at 11.850-11.950 EPS.</p>

Swiss National Bank Has $84.12 Million Stake in IQVIA Holdings Inc. $IQV